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The human genome harbors an impressive number of genes
encoding enzymes that primarily metabolize or transport drugs
or other xenobiotics (XMEs). Genetic and functional varia-
tion in these genes is tremendous and has complex conse-
quences, depending, for example, on whether enzyme structure
or expression is affected, or whether the produced metabo-
lite is pharmacologically or toxicologically active or not.
Despite numerous impressive examples of the impact of genetic
variation on pharmacokinetics and drug response, today’s knowl-
edge is incomplete regarding most XME genes and fragmentary
even for many well-investigated XMEs. This is one of the rea-
sons why clinical pharmacogenetic studies are often controversial
and clinical application in personalized medicine is presently lim-
ited. Advanced technology and ongoing large-scale projects are
rapidly uncovering the existing genetic variation in all popula-
tions on earth, ultimately enabling the personal genome in the
very near future. A wealth of mostly rare novel variants is awaiting
functional characterization either by high-throughput expres-
sion/phenotyping techniques or by prediction using improved
algorithms to estimate functional relevance.
With this Research Topic we would like to give an up-to-date
overview about the current knowledge in this field by covering
both, known hard facts as well as cutting-edge advancement in
novel genetic and genomic variation of XMEs and their functional
consequences. Five major subtopics which include 20 research
or review papers are included in this E-book. These are the
following:
History and current knowledge of XMEs
• Clinical application of CYP2C19 pharmacogenetics toward
more personalized medicine (Lee, 2013, review).
• Pharmacogenetics of cytochrome P450 2B6 (CYP2B6):
advances on polymorphisms, mechanisms, and clinical
relevance (Zanger and Klein, 2013, review).
• Pharmacogenetics of human ABC transporter ABCC11: new
insights into apocrine gland growth and metabolite secretion
(Ishikawa et al., 2013, review).
• Pharmacogenomics of cytochrome P450 3A4: recent progress
toward the “missing heritability” problem (Klein and Zanger,
2013, review).
Clinical implications of XME gene variants
• ABCB1 4036A>G and 1236C>T polymorphisms affect plasma
efavirenz levels in South African HIV/AIDS patients (Swart
et al., 2012, research article).
• Genetic variations in drug-induced liver injury (DILI): resolv-
ing the puzzle (Stephens et al., 2012, opinion).
• MDMA, methamphetamine, and CYP2D6 pharmacogenet-
ics: what is clinically relevant? (de la Torre et al., 2012,
review).
• Molecular interactions between NAFLD and xenobiotic
metabolism (Naik et al., 2013, review).
• Toward a clinical practice guide in pharmacogenomics testing
for functional polymorphisms of drug-metabolizing enzymes.
Gene/drug pairs and barriers perceived in Spain (Agúndez
et al., 2012, perspective).
Inter/intraethnic variability of XME gene variants
• Characterization of the genetic variation present in CYP3A4
in three South African populations (Drögemöller et al., 2013,
research article).
• Frequencies of 23 functionally significant variant alleles related
with metabolism of antineoplastic drugs in the Chilean pop-
ulation: comparison with Caucasian and Asian populations
(Roco et al., 2012, research article).
• Pharmacogenomic diversity among Brazilians: influence
of ancestry, self-reported color, and geographical origin
(Suarez-Kurtz et al., 2012, review).
Regulation of XME gene expression
• Impact of the interaction between 3′-UTR SNPs and
microRNA on the expression of human xenobiotic metabolism
enzyme and transporter genes (Wei et al., 2012, research
article).
• Molecular mechanisms of genetic variation and transcriptional
regulation of CYP2C19 (Helsby and Burns, 2012, review).
Pharmacogenetics in cancer therapy
• Impact of genetic polymorphisms on chemotherapy toxicity
in childhood acute lymphoblastic leukemia (Gervasini and
Vagace, 2012, review).
• Multilocus genotypes of relevance for drug metaboliz-
ing enzymes and therapy with thiopurines in patients
with acute lymphoblastic leukemia (Stocco et al., 2013,
review).
• Functional polymorphisms in xenobiotic metabolizing
enzymes and their impact on the therapy of breast cancer
(Vianna-Jorge et al., 2013, review).
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• High-resolution melting analysis of the common
c.1905+1G>A mutation causing dihydropyrimidine dehydro-
genase deficiency and lethal 5-fluorouracil toxicity (Borràs
et al., 2013, research article).
• Polymorphisms of phase I and phase II enzymes and breast
cancer risk (Justenhoven, 2012, review).
• Analysis of the functional polymorphism in the cytochrome
P450CYP2C8 gene rs11572080 with regard to colorectal cancer
risk (Ladero et al., 2012, research article).
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